Sangamo Therapeutics (SGMO) Misses Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. PLTR
4. SPY
5. CSCO
6. KTOS
7. JPM
8. DT
9. AON
10. TMUS

Go back to Sangamo Therapeutics (SGMO) Misses Q1 EPS by 2c

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

May 14, 2026 4:01 PM EDT

Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress.

Six sites activated in Phase 1/2 STAND study evaluating ST-503 in chronic neuropathic pain.

Held productive interaction with U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to discuss prion disease study.

Participated in 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, showcasing progression of Sangamos neurology pipeline and advances in modular integrase technology.

RICHMOND, Calif., May 14, 2026 (GLOBE... More